Johnson & Johnson's most recent trend suggests a bullish bias. One trading opportunity on Johnson & Johnson is a Bull Put Spread using a strike $135.00 short put and a strike $125.00 long put offers a potential 5.93% return on risk over the next 28 calendar days. Maximum profit would be generated if the Bull Put Spread were to expire worthless, which would occur if the stock were above $135.00 by expiration. The full premium credit of $0.56 would be kept by the premium seller. The risk of $9.44 would be incurred if the stock dropped below the $125.00 long put strike price.
The 5-day moving average is moving up which suggests that the short-term momentum for Johnson & Johnson is bullish and the probability of a rise in share price is higher if the stock starts trending.
The 20-day moving average is moving up which suggests that the medium-term momentum for Johnson & Johnson is bullish.
The RSI indicator is above 80 which suggests that the stock is in overbought territory.
To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here
LATEST NEWS for Johnson & Johnson
Johnson & Johnson to Host Investor Conference Call on Third-Quarter Results
Wed, 19 Sep 2018 20:57:00 +0000
The webcast and presentation material are accessible at Johnson & Johnson's website www.investor.jnj.com. A replay of the webcast will be available approximately three hours after the conference call concludes.
Here’s a clear case for owning dividend stocks instead of bonds
Wed, 19 Sep 2018 19:20:00 +0000
Hank Smith, co-chief investment officer of Haverford Trust, has laid out a clear case for dividend stocks over bonds. Pepsi’s stock had a dividend yield of 3.25% as of the close on Sept. 18, while 10-year U.S. Treasury paper yielded 3.05%.
Taking Stock of Quest Diagnostics’ Recent Acquisitions
Wed, 19 Sep 2018 18:52:39 +0000
Quest Diagnostics’ (DGX) diagnostic information services (or DIS) business accounts for more than 95% of the company’s total revenues. It is characterized by a high volume of relatively low-dollar transactions. Under DIS, Quest provides clinical testing and other services. Major customer groups for DIS include healthcare insurers, government payers, client payers, and patients.
How Quest Diagnostics Is Positioned in 2018
Wed, 19 Sep 2018 18:52:38 +0000
Quest Diagnostics (DGX) is a leading provider of diagnostic information services. Quest makes use of its database of clinical lab results to gain diagnostic insights that help to improve healthcare management. Quest’s diagnostics information services business (or DIS) provides data and insights based on routine, non-routine, and advanced clinical testing, as well as anatomic pathology testing and other diagnostic information services.
J&J Files NDA for Erdafitinib in Urothelial Cancer Indication
Wed, 19 Sep 2018 15:05:03 +0000
Johnson & Johnson (JNJ) submits regulatory application to the FDA seeking approval of pan-FGFR inhibitor, erdafitinib, for the treatment of metastatic urothelial cancer, a type of bladder cancer.
Also on Market Tamer…
Follow Us on Facebook